ResMed’s $255 Price Target Signals 11.7% Upside as Insiders Sell $1.5M Shares
Evercore ISI raised ResMed’s price target to $255, implying an 11.7% upside from the current $228.33 share price, while CEO Michael Farrell and Director Peter Farrell sold over $1.5 million in shares under pre-arranged plans. Investors await Q3 2026 results on April 30, as market cap stands at $32.7 billion.
1. Price Target Revision
Evercore ISI increased its price target for ResMed to $255, suggesting an 11.68% gain from the prevailing $228.33 share price and reflecting bullish expectations for the company’s growth in respiratory care devices.
2. Insider Sales Details
CEO Michael Farrell sold 4,991 shares for over $1.1 million and Director Peter Farrell disposed of 2,000 shares worth $450 thousand, both transactions executed under pre-arranged trading plans.
3. Market Capitalization and Share Range
ResMed shares have traded between $202.00 and $293.81 over the past 12 months, with the company currently valued at $32.67 billion in market capitalization.
4. Upcoming Earnings Report
ResMed is scheduled to report its Q3 2026 earnings on April 30, when investors will assess revenue trends, device sales growth and profitability metrics.